Summit Therapeu ADR (SMMT)

$15.51 -0.21 (-1.34%)
Market Cap 12.03B
Revenue (ttm) 0.00
Net Income (ttm) -1.08B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,872,700
Avg Vol 2,652,638
Day's Range N/A - N/A
Shares Out 775.37M
Stochastic %K 18%
Beta -1.43
Analysts Strong Sell
Price Target $29.79

Company Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical...

Industry: Biotechnology
Sector: Healthcare
Phone: 305 203 2034
Address:
601 Brickell Key Drive, Suite 1000, Miami, United States
Mariabronn
Mariabronn Mar. 21 at 9:17 PM
$SMMT
0 · Reply
charlief
charlief Mar. 21 at 5:35 PM
$SMMT
0 · Reply
TruthBroker2
TruthBroker2 Mar. 20 at 8:28 PM
$SMMT
0 · Reply
Mariabronn
Mariabronn Mar. 20 at 3:20 PM
$SMMT
0 · Reply
TruthBroker2
TruthBroker2 Mar. 20 at 3:01 PM
$SMMT
0 · Reply
SmokeWagon
SmokeWagon Mar. 20 at 2:12 PM
$SMMT !!!
0 · Reply
Magic8BallResponse
Magic8BallResponse Mar. 20 at 1:41 PM
$SMMT Time for BOBBY to MAKE A DEAL..... Where are those golden hands????
0 · Reply
DragonAlgo
DragonAlgo Mar. 20 at 5:06 AM
🐉 $SMMT CALL — DragonAlgo® Signal Contract: SMMT CALL Expiry: 2026-03-20 | Strike: $15.50 | Type: CALL Option Plan (premium): Entry: $0.42 Stop: $0.30 TP1: $0.55 TP2: $0.71 TP3: $1.01 🔗 https://dragonalgo.com
0 · Reply
TruthBroker2
TruthBroker2 Mar. 19 at 7:28 PM
$SMMT
0 · Reply
SellasgpsCurativeBAT9
SellasgpsCurativeBAT9 Mar. 19 at 6:50 PM
$SLS $SMMT $IBRX $ABVX My Brothers and sisters let me give you some examples of a positive Oncology phase 3 SMMT went from $4.00 to $44.00 after Harmoni phase 3 and MC of $26 Billion. ABVX went from a $4.50 to $140.00 after phase 3. IBRX went from to $2.00 to $12.00 with a billion shares out. NONE of the 👆 is CURATIVE. 🎤 ✌️🙏❤️‍🩹
0 · Reply
Latest News on SMMT
Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 Transcript

Mar 11, 2026, 4:22 PM EDT - 10 days ago

Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 Transcript

Summit Therapeutics Inc. (SMMT) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 2, 2026, 4:57 PM EST - 19 days ago

Summit Therapeutics Inc. (SMMT) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Summit Therapeutics to Present at Upcoming Investor Conferences

Feb 26, 2026, 6:45 PM EST - 23 days ago

Summit Therapeutics to Present at Upcoming Investor Conferences

Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 3:54 AM EST - 25 days ago

Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

Feb 23, 2026, 4:05 PM EST - 26 days ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

Feb 17, 2026, 5:05 PM EST - 4 weeks ago

Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 30, 2026, 4:30 PM EST - 7 weeks ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy

Jan 29, 2026, 7:30 AM EST - 7 weeks ago

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy

Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 3:56 PM EST - 2 months ago

Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

Jan 12, 2026, 6:15 AM EST - 2 months ago

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

GSK

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Jan 12, 2026, 6:00 AM EST - 2 months ago

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:30 AM EST - 2 months ago

Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 9:43 PM EST - 3 months ago

Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript

Summit Therapeutics Inc. (SMMT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 2, 2025, 5:13 PM EST - 3 months ago

Summit Therapeutics Inc. (SMMT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying

Nov 19, 2025, 4:26 AM EST - 4 months ago

Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying

Summit Therapeutics Inc. (SMMT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 18, 2025, 12:38 PM EST - 4 months ago

Summit Therapeutics Inc. (SMMT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Summit Therapeutics Inc. (SMMT) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 4:11 AM EST - 4 months ago

Summit Therapeutics Inc. (SMMT) Presents at UBS Global Healthcare Conference 2025 Transcript

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

Nov 7, 2025, 9:00 AM EST - 4 months ago

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Oct 31, 2025, 7:00 AM EDT - 5 months ago

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Summit Therapeutics Raises $500 Million in Private Placement

Oct 22, 2025, 8:00 AM EDT - 5 months ago

Summit Therapeutics Raises $500 Million in Private Placement

Summit Therapeutics Inc. (SMMT) Q3 2025 Earnings Call Transcript

Oct 20, 2025, 5:05 PM EDT - 5 months ago

Summit Therapeutics Inc. (SMMT) Q3 2025 Earnings Call Transcript

Summit's Bold BLA Without Stat-Sig OS: Why I Step Back To Hold

Oct 20, 2025, 2:35 PM EDT - 5 months ago

Summit's Bold BLA Without Stat-Sig OS: Why I Step Back To Hold

What's Going On With Summit Therapeutics Stock On Monday?

Oct 20, 2025, 10:05 AM EDT - 5 months ago

What's Going On With Summit Therapeutics Stock On Monday?

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Oct 20, 2025, 6:45 AM EDT - 5 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Oct 19, 2025, 10:30 AM EDT - 5 months ago

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

Oct 17, 2025, 7:00 AM EDT - 5 months ago

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

Oct 15, 2025, 7:00 AM EDT - 5 months ago

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

Sep 24, 2025, 7:00 AM EDT - 6 months ago

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

Ten Bull Market 10-Baggers

Sep 22, 2025, 2:45 PM EDT - 6 months ago

Ten Bull Market 10-Baggers

APP CVNA FTAI HOOD MSTR NVDA PLTR

Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential

Sep 17, 2025, 10:54 PM EDT - 6 months ago

Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 16, 2025, 4:31 PM EDT - 6 months ago

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 10, 2025, 12:43 AM EDT - 6 months ago

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Top 3 Health Care Stocks You'll Regret Missing In Q3

Sep 9, 2025, 9:12 AM EDT - 6 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q3

LNAI

Summit Therapeutics (SMMT) WCLC Update Call (Transcript)

Sep 8, 2025, 3:36 PM EDT - 6 months ago

Summit Therapeutics (SMMT) WCLC Update Call (Transcript)

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences

Sep 8, 2025, 8:28 AM EDT - 6 months ago

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences

New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Sep 8, 2025, 8:10 AM EDT - 6 months ago

New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

NFE

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Sep 7, 2025, 6:08 AM EDT - 6 months ago

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Sep 7, 2025, 3:30 AM EDT - 6 months ago

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

Sep 3, 2025, 7:00 AM EDT - 7 months ago

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Aug 27, 2025, 2:43 PM EDT - 7 months ago

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Aug 14, 2025, 7:00 AM EDT - 7 months ago

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

Aug 11, 2025, 5:03 PM EDT - 7 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Jul 14, 2025, 3:00 PM EDT - 8 months ago

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

Jul 4, 2025, 5:10 AM EDT - 9 months ago

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

AZN

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

Jun 30, 2025, 8:00 AM EDT - 9 months ago

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

RVMD

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 5, 2025, 8:00 AM EDT - 10 months ago

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Mariabronn
Mariabronn Mar. 21 at 9:17 PM
$SMMT
0 · Reply
charlief
charlief Mar. 21 at 5:35 PM
$SMMT
0 · Reply
TruthBroker2
TruthBroker2 Mar. 20 at 8:28 PM
$SMMT
0 · Reply
Mariabronn
Mariabronn Mar. 20 at 3:20 PM
$SMMT
0 · Reply
TruthBroker2
TruthBroker2 Mar. 20 at 3:01 PM
$SMMT
0 · Reply
SmokeWagon
SmokeWagon Mar. 20 at 2:12 PM
$SMMT !!!
0 · Reply
Magic8BallResponse
Magic8BallResponse Mar. 20 at 1:41 PM
$SMMT Time for BOBBY to MAKE A DEAL..... Where are those golden hands????
0 · Reply
DragonAlgo
DragonAlgo Mar. 20 at 5:06 AM
🐉 $SMMT CALL — DragonAlgo® Signal Contract: SMMT CALL Expiry: 2026-03-20 | Strike: $15.50 | Type: CALL Option Plan (premium): Entry: $0.42 Stop: $0.30 TP1: $0.55 TP2: $0.71 TP3: $1.01 🔗 https://dragonalgo.com
0 · Reply
TruthBroker2
TruthBroker2 Mar. 19 at 7:28 PM
$SMMT
0 · Reply
SellasgpsCurativeBAT9
SellasgpsCurativeBAT9 Mar. 19 at 6:50 PM
$SLS $SMMT $IBRX $ABVX My Brothers and sisters let me give you some examples of a positive Oncology phase 3 SMMT went from $4.00 to $44.00 after Harmoni phase 3 and MC of $26 Billion. ABVX went from a $4.50 to $140.00 after phase 3. IBRX went from to $2.00 to $12.00 with a billion shares out. NONE of the 👆 is CURATIVE. 🎤 ✌️🙏❤️‍🩹
0 · Reply
SmokeWagon
SmokeWagon Mar. 19 at 3:58 PM
$SMMT !!!
0 · Reply
TruthBroker2
TruthBroker2 Mar. 19 at 3:16 PM
$SMMT
0 · Reply
TruthBroker2
TruthBroker2 Mar. 19 at 12:26 PM
$SMMT
0 · Reply
sasanalyst
sasanalyst Mar. 19 at 12:47 AM
$SMMT Fuck the Jefferies, Bob open your wallet now.
0 · Reply
TruthBroker2
TruthBroker2 Mar. 18 at 8:36 PM
$SMMT Be lookin Good 👍
0 · Reply
Magic8BallResponse
Magic8BallResponse Mar. 18 at 8:32 PM
$SMMT Horrible trend. Folks want the DATA
0 · Reply
TruthBroker2
TruthBroker2 Mar. 18 at 7:48 PM
$SMMT
0 · Reply
Magic8BallResponse
Magic8BallResponse Mar. 18 at 7:02 PM
$SMMT Bobby?
0 · Reply
TruthBroker2
TruthBroker2 Mar. 18 at 6:05 PM
$SMMT
0 · Reply
Magic8BallResponse
Magic8BallResponse Mar. 18 at 5:56 PM
$SMMT Any data pointing to OSS? Please point me in the direction
0 · Reply
TruthBroker2
TruthBroker2 Mar. 18 at 5:52 PM
$SMMT Florida 👍 in his penthouse hes da man 😆 better cover
0 · Reply
Magic8BallResponse
Magic8BallResponse Mar. 18 at 5:24 PM
$SMMT WHERE IS BOBBY???
1 · Reply